1. Total thyroidectomy can be overtreatment in cN1a papillary thyroid carcinoma patients whose tumor is smaller than 1 cm
- Author
-
Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Ji Yeon Lee, Young Lyun Oh, and Kyorim Back
- Subjects
Total thyroidectomy ,medicine.medical_specialty ,Overtreatment ,Tumor size ,business.industry ,Thyroid ,Papillary Thyroid Microcarcinoma ,General Medicine ,Carcinoma, Papillary ,Nodal disease ,Surgery ,Thyroid carcinoma ,Dissection ,medicine.anatomical_structure ,Thyroid Cancer, Papillary ,Thyroidectomy ,Humans ,Medicine ,In patient ,Thyroid Neoplasms ,Neoplasm Recurrence, Local ,business ,Retrospective Studies - Abstract
Background The 2015 American Thyroid Association (ATA) guidelines recommend pursuing total thyroidectomy with therapeutic central lymph-node dissection (CND) in patients with clinically apparent nodal disease (cN1a), regardless of tumor size. The aim of this study was to investigate whether total thyroidectomy is necessary for thyroid papillary microcarcinoma (PTMC) patients with preoperative unilateral cN1a. Methods This study included 295 papillary thyroid microcarcinoma patients who underwent total thyroidectomy with bilateral CND from January 2012 to June 2015. Results The median follow-up time was 42.5 months. Locoregional recurrence (LRR) was observed in only two (0.9%) patients. Among 70 cN1a patients, only 19 (27.1%) were at intermediate risk for disease recurrence and required total thyroidectomy per the ATA guidelines. Lobectomy can be considered as a treatment option for the remaining patients (72.9%). Conclusions Our study showed that more than two-thirds of PTMC patients with clinical nodal disease who underwent total thyroidectomy and CND were actually lobectomy candidates. Total thyroidectomy as the first surgical option for cN1a, especially in PTMC patients, should be reconsidered.
- Published
- 2022
- Full Text
- View/download PDF